Buformin

Summary

Buformin (CHEMBL39736) is an approved small-molecule hypoglycemic agent (ATC A10BA03); indicated across 1 condition including diabetes mellitus.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A10BA03
• Indications: 1 condition
• Chemistry: 157.22 Da · C6H15N5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL39736
Name	Buformin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2468
ChEBI	CHEBI:3209
ATC	A10BA03
Molecular formula	C6H15N5
Molecular weight	157.22
InChIKey	XSEUMFJMFFMCIU-UHFFFAOYSA-N

SMILES: CCCCN=C(N)N=C(N)N

IUPAC name: 2-butyl-1-(diaminomethylidene)guanidine

ChEBI definition: A member of the class of biguanides that is biguanide substituted by a butyl group at position 1. It is an antidiabetic drug with potential antitumor effect.

Pharmacological roles (ChEBI): hypoglycemic agent, geroprotector, radiosensitizing agent, antineoplastic agent, antiviral agent.

Also known as: Buformin, Buformin hydrochloride, Buformina, Buformine, DBV, W 37, W-37, SID26757952, BUFORMIN, SID144205717, buformin, BUFORMINE

Patent coverage: 5,961 distinct patent families (21,976 SureChEMBL compound mentions), from 5 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prelamin-A/C.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	5.5	Potency	3162	nM	CHEMBL_ACT_3667724

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diabetes mellitus	4	MONDO:0005015	EFO:0000400

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).